Roivant Sciences Ltd.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-189.8M | $303.0M | $-265.9M | $-113.5M | $-223.4M | $-206.5M | $169.4M | $-230.2M |
| Depreciation & Amortization | $600.0K | $638.0K | $691.0K | $921.0K | $1.1M | $1.4M | $2.9M | $4.8M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $83.3M | $77.2M | $105.0M | $81.8M | $82.2M | $83.5M | $83.7M | $71.7M |
| Net Cash from Operating Activities | $-270.5M | $-163.8M | $-196.5M | $-185.7M | $-204.4M | $-172.6M | $-207.3M | $-266.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $419.0K | $1.3M | $-4.9M | $7.8M | $4.0M | $811.0K | $1.8M | $996.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $281.3M | $173.5M | $109.5M | $120.4M | $-1.09B | $1.07B | $454.1M | $-3.29B |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $206.7M | — | $0 | $0 | $208.3M | $295.4M | $243.3M | $106.1M |
| Net Cash from Financing Activities | $-181.5M | $-68.8M | $328.2M | $62.6M | $-187.8M | $-177.2M | $-273.0M | $-109.1M |
| Net Change in Cash | $-170.4M | $-57.8M | $241.6M | $-1.4M | $-1.48B | $724.0M | $-27.2M | $-3.66B |
| Free Cash Flow | $-270.9M | $-165.1M | $-191.5M | $-193.5M | $-208.4M | $-173.4M | $-209.1M | $-267.8M |